ICYMI: I-MAK: Cracking Down on Big Pharma’s Patent Abuse to Lower Drug Prices Should Be Bipartisan Priority
Non-Profit Advocates for Affordable Prescription Drug Prices Call on Congress… Read More
© 2026 CSRXP- All Rights Reserved
DOSE OF REALITY: BIG PHARMA’S PATENT THICKETS COST PATIENTS AND TAXPAYERS BILLIONS IN LOST SAVINGS EACH YEAR
New Matrix Global Advisors Report Shines Light on Cost of Big Pharma’s… Read More
CSRXP POLL: VOTERS OVERWHELMINGLY SUPPORT HOLDING BIG PHARMA ACCOUNTABLE TO BUILD ON POSITIVE PROGRESS TOWARD LOWERING RX PRICES
Broad Majorities Reject Big Pharma’s Blame Game and Want Policymakers to… Read More
CSRXP: BIG PHARMA DOUBLES DOWN ON BUSINESS-AS-USUAL AS JANUARY PRICE HIKES CLIMB TO 587
Brand Name Drug Companies Increase Prices on Treatments for Serious Conditions… Read More
CSRXP: MODERNA’S 500 PERCENT VACCINE PRICE HIKE A BRAZEN DEMONSTRATION OF BIG PHARMA’S GREED
Brand Name Drug Companies Continue Seeking to Price-Gouge COVID-19 Treatments… Read More
ICYMI: STUDY FINDS MEDICARE PART B WOULD HAVE SAVED $3.7 BILLION OVER THREE YEARS IF BIG PHARMA’S PRICE HIKES WERE BELOW THE RATE OF INFLATION
Analysis Finds Drug Companies Increased Prices Faster Than the Rate of… Read More
BIG PHARMA WATCH: BIG PHARMA SET RECORD FOR OUT-OF-CONTROL LAUNCH PRICES IN 2022 AS MEDIAN PRICE OF NEW TREATMENTS SURGED PAST $220,000
Brand Name Drug Companies Setting Egregious Prices on New Products Not… Read More
BIG PHARMA WATCH: U.S. HOUSE REPORT DETAILS “UNJUSTIFIABLY HIGH PRICE” OF UNPROVEN ALZHEIMER’S DRUG ADUHELM
Congressional Probe Concludes Biogen Set Egregious Price Tag on Aduhelm to… Read More
CSRXP: BIG PHARMA WELCOMES NEW YEAR BY HIKING PRICES ON HUNDREDS OF PRESCRIPTION DRUGS
Brand Name Drug Companies Maintain Business-as-Usual Approach to Price-Gouging… Read More
DOSE OF REALITY: BREAKING DOWN BIG PHARMA’S YEAR OF BAD BEHAVIOR IN 2022
Get the Facts on Big Pharma’s Year of Out-of-Control Launch Prices… Read More
TWO BIRDS OF A FEATHER: BIG PHARMA PRICE HIKERS TO JOIN FORCES IN LARGEST HEALTH CARE MERGER OF THE YEAR
Amgen and Horizon Therapeutics Eye Merger As Both Continue to Hike Prices on… Read More
SECOND OPINION: BIG PHARMA EXEC BOOED AS HE DISMISSES AFFORDABILITY CONCERNS ON HIGH PRICED TREATMENTS AS “LUDICROUS”
Regeneron Co-Founder Says, “Forget About That” When Pressed on How… Read More